title: Epidemiology and management of refractory lupus nephritis.
abstract: Although the survival of patients with lupus nephritis (LN) has improved considerably in recent years, refractory LN appears in a substantial proportion of patients and, therefore, treatment of LN remains a real challenge today. We will use the term "refractory" LN, for those cases with none or partial response to first-line therapies. In this sense, numerous epidemiological factors, including racial, socioeconomic, histological and serological parameters, may influence treatment response and, therefore, may have an impact on the outcome of renal involvement. Initial conventional therapy will depend somewhat on these epidemiological factors. If this initial therapy fails, fortunately today we have alternative therapies that include the multitarget therapy and the use of biologics. Published evidence about these therapies is presented in this review. Important terms in the management of LN, such as the definition of complete response, partial response, sustained response and renal flare as well as the discrimination of different types of flare, are also discussed here according to the European consensus statement on the terminology used in the management of lupus glomerulonephritis.
authors.affiliation: Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain.
authors.forename: Guillermo J
authors.initials: GJ
authors.lastname: Pons-Estel
authors.forename: Rosa
authors.initials: R
authors.lastname: Serrano
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Plasín
authors.forename: Gerard
authors.initials: G
authors.lastname: Espinosa
authors.forename: Ricard
authors.initials: R
authors.lastname: Cervera
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D065095:Calcineurin Inhibitors; D002986:Clinical Trials as Topic; D018450:Disease Progression; D005006:Ethnicity; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007167:Immunotherapy; D008181:Lupus Nephritis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology* / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D012307:Risk Factors; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000069283:Rituximab